Report of Foreign Issuer (6-k)
30 September 2015 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2015
Commission File Number: 001-36596
___________________
TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)
96 Skyway Avenue
Toronto, Ontario M9W 4Y9
Canada
(Address of principal executive offices)
___________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form
40-F [X]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Trillium Therapeutics Inc. |
|
|
|
|
Date: September 29, 2015 |
|
|
By: /s/ James
Parsons
|
|
Name: James Parsons |
|
Title: Chief Financial Officer
|
2
EXHIBIT INDEX
FOR IMMEDIATE RELEASE |
NASDAQ:TRIL |
|
TSX: TR |
TRILLIUM THERAPEUTICS PROVIDES UPDATE ON CD47
PROGRAM
Toronto, Canada September 30, 2015 Trillium
Therapeutics Inc. (NASDAQ: TRIL; TSX: TR) an immuno-oncology company
developing innovative therapies for the treatment of cancer, today announced
that it has completed the manufacture of clinical-grade drug product, concluded
a comprehensive IND-enabling non-clinical safety assessment program, and has
proposed a design for its first-in-human clinical trial with TTI-621
(SIRPaFc).
The Company plans to conduct a Phase I trial with a
dose-escalation stage that will enroll patients with relapsed or refractory
lymphoma who are transfusion independent with relatively normal baseline blood
counts, thus better enabling characterization of potential changes in
hematologic parameters that could occur upon CD47 blockade. Once the optimal
dose and schedule of TTI-621 administration have been established, the Company
expects to study safety and anti-tumor activity in a variety of expansion
cohorts of patients. These will include patients with acute myeloid leukemia,
myelodysplastic syndrome, as well as several other advanced hematologic
malignancies.
The Investigational New Drug application was submitted as
planned and we have secured enthusiastic commitments from multiple investigators
at key cancer treatment centers in the United States, commented Dr. Eric
Sievers, Trilliums Chief Medical Officer. We have been gratified by
considerable interest from the oncology community to evaluate a novel checkpoint
inhibitor of the innate immune system.
Additional in vitro and in vivo preclinical
studies have been completed. These have demonstrated that TTI-621 has potent
anti-tumor activity across a range of hematological tumors, and have provided
guidance for the expansion cohorts in the first-in-human clinical study. The
Company expects to present some of these data at an upcoming scientific meeting.
The Company also continues to explore the therapeutic potential
of TTI-621 in a variety of solid tumor models, both as monotherapy and in
combination with other therapeutic agents. Based on the results of these
studies, as well as on third party data reported in the literature, additional
clinical trials will be designed.
About Trillium Therapeutics:
Trillium Therapeutics
Inc. is an immuno-oncology company developing innovative therapies for the
treatment of cancer. The Companys lead program is a SIRPaFc antibody-like
fusion protein that blocks the activity of CD47, a molecule that is upregulated
on a wide variety of tumors. CD47 binds to SIRPa on macrophages and delivers a
do not eat signal that inhibits the ability of macrophages to phagocytose
(engulf and destroy) malignant cells.
For more information visit: www.trilliumtherapeutics.com
Caution Regarding Forward-Looking Information:
This
press release may contain forward-looking statements, which reflect Trilliums
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such risks
and uncertainties, including our expectations about the nature and timing of
clinical development plans and future presentations, are described in the
companys ongoing quarterly and annual reporting. Except as required by
applicable securities laws, Trillium undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of the TSX) accepts responsibility for the adequacy
or accuracy of this release.
Contact:
Trillium Therapeutics Inc.
James
Parsons
Chief Financial Officer
+1 416 595 0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
-2-
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From May 2024 to Jun 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jun 2023 to Jun 2024